Aqueous formulations of (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate
The invention relates to aqueous formulations containing (−)-(R)-3-(2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluobutane-1-sulfonate. Said formulations are suitable as infusion solutions or as concentrate for producing these infusion solutions.
1 . An aqueous formulation comprising (−)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate (I) and cyclodextrin.
2 . A formulation as claimed in claim 1 , comprising from 0.00005 to 9.0 g/l of the compound (I) and from 0.1 to 550 g/l of cyclodextrin.
3 . A formulation as claimed in either of the preceding claims, comprising from 0.0001 to 0.050 g/l of the compound (I) and from 0.2 to 200 g/l cyclodextrin.
4 . A formulation as claimed in any of the preceding claims, comprising from 0.0005 to 0.025 g/l of the compound (I) and from 1 to 50 g/l cyclodextrin.
5 . A formulation as claimed in any of the preceding claims, which has a pH of from 2 to 6.
6 . A formulation as claimed in any of the preceding claims, comprising at least one physiologically tolerated acid.
7 . A formulation as claimed in claim 6 , which comprises citric acid as physiologically tolerated acid.
8 . A formulation as claimed in any of the preceding claims, comprising from 8 to 10 g/l sodium chloride based on the formulation ready for use.
9 . A formulation as claimed in any of the preceding claims, comprising from 0.05 to 2 g/l ethanol based on the formulation ready for use.
10 . An administration kit consisting of
a) a container comprising the aqueous formulation as claimed in claims 1 to 9 ,
b) infusion apparatus, where at least the parts which come into contact with the product consist of polyethylene, polypropylene, polyester, polyamide, acrylonitrile-butadiene-styrene copolymers, polypropylene/styrene-ethylene-butylene-styrene or copolymers thereof.